Patient characteristics
androtinib
The median age of the 33 patients was 63 years (range 48–74 years), 87.9% (4/33) were men, 91% had an ECOG score of 1 (30/33), and smoking accounted for 54.5% (18/33). The follow-up treatment received by the subjects included two cases of reuse of other immunotherapy, two cases of radiotherapy, one case of particle implantation, five cases of chemotherapy, three cases of androtinib treatment, and two cases of optimal supportive treatment. The detailed characteristics of the patients are shown in Baseline characteristics.